Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Exclusive distribution agreement for chemotherapy products Etopophos® and Vepesid® in Australia and New Zealand

Posted by fidest press agency su martedì, 3 settembre 2019

CHEPLAPHARM acquired the global rights to the products from Bristol-Myers Squibb (BMS) in August 2018. CHEPLAPHARM has global capabilities in manufacturing and distribution and will continue to supply and provide access to these medicines for patients. Clinigen has been appointed by CHEPLAPHARM to distribute Etopophos® and Vepesid® via the Group’s extensive infrastructure in Australia and New Zealand as part of CHEPLAPHARM’S network of exclusive cooperation partners.Etopophos® and Vepesid® are etoposide products, a drug which is included on the World Health Organization Model List of Essential Medicines and is considered an essential medicine for priority diseases. Etopophos® and Vepesid® are currently approved for the treatment of:Small Cell Lung Cancer – in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer Hodgkin’s Disease Malignant (non-Hodgkin’s) lymphomas, especially of the histiocytic variety Acute non-lymphocytic leukaemia Testicular tumours in combination regimens for the treatment of refractory testicular tumours Etopophos® is also indicated as part of first-line combination regimens for the treatment of testicular tumours.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: